
October 7, 2026 Base-editing innovator and longtime local supporters to receive PRF’s S.A.M. Award and Amy Award at biennial signature event


October 7, 2026 Base-editing innovator and longtime local supporters to receive PRF’s S.A.M. Award and Amy Award at biennial signature event

A MILESTONE DECADES IN THE MAKING: Four Adults Making Progeria History!

March 3, 2026 PRF Announces Manufacturing Partnership with Forge Biologics to Advance Progeria Gene Therapy!
This announcement marks a major milestone: PRF has entered into a manufacturing agreement with Forge Biologics to produce SamPro-2, its gene editing therapy in development for children and young adults with Progeria — an essential step toward clinical trials and, ultimately, the cure!
For more than 25 years, PRF has been setting the standard for ultrarare disease research. Donor and volunteer support has made it possible to identify and support children and families worldwide, fund critical research, and develop therapies that would not exist otherwise. When no clear path from discovery to treatment existed, we built one.
And we’re not done.